Access to Inpatient Hospital Drug Utilization Data
Contact and place of performance
Robin Goon
Silver Spring, MD 20993
USA
The FDA's Office of Surveillance and Epidemiology (OSE) requires access to inpatient hospital drug utilization data in order to evaluate drug risks and promote the safe use of drugs by the American people.The statutory provisions of the Federal Food, Drug, and Cosmetic Act as amended by the Food and Drug Administration Modernization Act (FDAMA, Section 406), Title 21 Code of Federal Regulations, Section 310.305, and...
View moreThe Food and Drug Administration (FDA) Office of Surveillance and Epidemiology (OSE) requires continued direct access to commercially available inpatient hospital drug utilization data and regulatory drug utilization services. This initiative supports the agency’s mandate under the Federal Food, Drug, and Cosmetic Act to ensure the safety and effectiveness of regulated marketed products. The data provides a necessary denominator for understanding adverse event reports, modeling drug risk based on usage patterns, and calculating patient-based reporting rates for drugs administered in hospital settings to both adult and pediatric populations. Furthermore, these resources enable the FDA to conduct regulatory impact studies under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act by comparing actual clinical use against recommended labeling.
The FDA Office of Acquisition and Grant Services is conducting this procurement under solicitation number 75F40120R00009. The opportunity is classified under NAICS 518210 for Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services and PSC B537 for Special Studies/Analysis- Medical/Health. This combined synopsis and solicitation includes five attachments, featuring the formal Request for Proposals, an IDIQ pricing worksheet, a Statement of Work for the first task order, and an amendment providing responses to vendor questions.
Performance will take place in Silver Spring, Maryland, with Robin Goon serving as the primary point of contact. Responses to the solicitation are due by February 11, 2020. The project aims to accelerate the FDA's regulatory decision-making process by providing real-time access to data that complements existing passive reporting systems and strengthens the overall Drug Utilization Program.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.